Oxazepam

Evidence Level: L3

Predicted Indications: 1

Oxazepam

Pharmacist Assessment Report

Oxazepam: From Alcohol Withdrawal Delirium and Anxiety to Insomnia

One-Sentence Summary

Oxazepam is a short-acting benzodiazepine, originally used for alcohol withdrawal delirium and anxiety. The TxGNN model predicts it may be effective for insomnia, with no registered clinical trials and 10 publications (including 3 small randomised trials from the 1980s and one from 2018) currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Alcohol withdrawal delirium; anxiety (the ARTG entry carries no approved indication text)
Predicted New Indication	Insomnia
TxGNN Prediction Score	0.9986
Evidence Level	L3
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on known class pharmacology, oxazepam is a benzodiazepine that enhances GABA-A receptor signalling, producing anxiolytic and sedative-hypnotic effects. Its efficacy in anxiety and alcohol withdrawal is established, and mechanistically it may be applicable to insomnia.

Anxiety and insomnia commonly occur together, and the GABA-A pathway that drives anxiolysis also shortens sleep latency and may help sleep maintenance. Short-acting benzodiazepines have long been used as hypnotics. Oxazepam’s lack of active metabolites and its glucuronidation-based clearance are sometimes cited as advantages in older people.

The supporting studies are old (1980s), small, and methodologically limited. Reviews also highlight dependence, falls and cognitive effects in older adults. This is class-level inference rather than new oxazepam-specific evidence.

The model also ranked 9 other diseases. Only alcohol withdrawal falls within the original indication scope, so it is not a true repurposing candidate. The remaining candidates have no meaningful therapeutic evidence: either no literature at all, or only toxicology and analytical papers.

Clinical Trial Evidence

Currently no related clinical trials registered for insomnia.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
6691478	1984	RCT	Am J Psychiatry	Oxazepam and flurazepam improved some polysomnographic measures in 14 patients with chronic insomnia; flurazepam caused marked daytime sleepiness, oxazepam did not
29749262	2018	RCT	Ann Pharmacother	Melatonin compared with oxazepam for anxiety and sleep quality in patients with STEMI after primary PCI
17317444	2007	Review/observational	Arch Gerontol Geriatr	Effectiveness and safety of hypnotics in 60 people over 70 with insomnia and comorbidities
23330992	2013	Review	Expert Opin Drug Metab Toxicol	Pharmacokinetics of anxiolytic drugs, relevant to anxiety disorders and drug selection
36340306	2022	Review	J Clin Exp Hepatol	Management of alcohol withdrawal in alcoholic liver disease (insomnia noted as a symptom)
29844949	2018	Cohort	PeerJ	Factors associated with potentially inappropriate long-term benzodiazepine and z-drug use in older people
6139491	1983	Cohort/case series	JAMA	Withdrawal syndrome in two patients after substituting short-acting for long-acting benzodiazepines (including oxazepam)

Several further small RCTs compare oxazepam versus midazolam (6138067, 6138069, 6138068) and versus valerian (10899744), and a review covers benzodiazepines for insomnia in older adults (7595266). These are all 1983 to 2000 studies with limited rigour.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 3132W	Alepam 15	Tablet 15 mg (oral)	Not stated in the data compiled for this report

Safety Considerations

Contraindication signals (from knowledge-graph drug-disease links, not label text): anxiety and neurotic disorders, porphyria, kidney disease, liver disease, gallbladder disease, psychotic and personality disorders, hypotensive disorders, sleep apnoea syndromes, respiratory failure and lung disease, substance-related disorders and dependence, and intermittent explosive disorder. Several of these (substance dependence, respiratory disease, sleep apnoea) are directly relevant to a hypnotic indication.
Drug interactions: 100 interactions were recorded. Major interactions include morphine (including liposomal morphine), consistent with additive central nervous system and respiratory depression. Moderate interactions include bupropion, dronabinol, nabilone, metoclopramide, opium, sibutramine and teduglutide. Antacids and calcium or magnesium products are minor.
Literature-based concerns: dependence, withdrawal (including rebound insomnia), abuse liability, and falls and cognitive effects in older adults.

Please refer to the TGA-approved Product Information (PI) for the full warnings and contraindications, as these were not available in the data compiled for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanism is plausible and short-term efficacy is suggested by small, old trials, but there are no registered trials, the evidence is rated L3, and the benefit-risk profile is unfavourable compared with current insomnia options because of dependence, withdrawal and sedation risks. The predicted indication is therefore best treated as a research question, not a basis for a change in use.

To proceed, the following is needed:

Mechanism of action data for oxazepam
TGA Product Information warnings and contraindications (a blocking gap for safety screening)
Approved indication text for the ARTG entry
Comparison against current guideline-recommended insomnia treatments, with a focus on older adults
A defined short-term, low-dose use case, and a dependence and withdrawal risk-mitigation plan, supported by modern controlled trial data

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.